Company intelligence / Profile preview

Res Novare

San Diego, California, United Statesresnovare.it ↗

Ownership: Private
Development stage: Commercial

Overview

Res Nova Bio has developed novel immunotherapies that target tumor-associated blood vessels to treat advanced breast cancer. Their lead program, FloraStilbene™, combines RU‑486 with pterostilbene to enhance immune response against tumors. Preclinical data show synergy with chemotherapy and checkpoint inhibitors. A Phase I/II trial has IRB clearance, with manufacturing partnership established for clinical supply. Another program, StemVacs-V, is in Phase II development for metastatic breast cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeImmunotherapy
Industry: Biotech

Partnerships

Cure Stat Rx – compounding pharmacy partner for clinical supply of FloraStilbene™

Beyond the preview

Go deeper on Res Novare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Res Novare.

Explore the full profile